Inclusion Criteria:

1. All patients must sign an informed consent indicating that they are aware of the
investigational nature of this study in keeping with the policies of this hospital.

2. Patients with histologically proven supratentorial anaplastic oligodendrogliomas,
anaplastic mixed oligoastrocytomas anaplastic astrocytomas or glioblastoma
multiforme.

3. Patients must have unequivocal evidence for tumor recurrence or progression by MRI
scan performed within 14 days prior to enrollment or documented recurrence by tumor
resection. Patients must have received radiation therapy previously.

4. Patients having undergone recent resection of recurrent or progressive tumor will be
eligible as long as all the following conditions are met: a) Patients have recovered
from the effects of surgery; b) Extent of residual disease (if present) has been
documented by MRI performed no later than 72 hours after surgery or, if not possible,
at least 4 weeks post-operative. Radiographic evidence of residual disease is not
mandated for enrollment.

5. The baseline on-study MRI is performed within 14 days of enrollment and on a steroid
dosage that has been stable. If the steroid dose is increased between the date of
imaging and the initiation of chemotherapy, a new baseline MRI is required on stable
steroids for 7 days.

6. Patients must be equal to or greater than 12 years old.

7. Patients must have a Karnofsky performance status of equal to or greater than 60
(Karnofsky Performance Scale; Appendix D).

8. Patients must have recovered from the toxic effects of prior therapy: 4 weeks from
prior cytotoxic therapy and/or at least two weeks from vincristine, 6 weeks from
nitrosoureas, 3 weeks from procarbazine administration, and 1 week for non-cytotoxic
agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc.
(radiosensitizer does not count). Any questions related to the definition of
non-cytotoxic agents should be directed to the Study Chair.

9. Patients must have adequate bone marrow function (ANC equal or greater than 1,500/mm3
and platelet count of equal or greater than 100,000/mm3), adequate liver function
(SGPT and alkaline phosphatase <2 times normal, bilirubin <1.5 mg%), and adequate
renal function (BUN and creatinine <1.5 times institutional normal) prior to starting
therapy.

Exclusion Criteria:

1. Patients with a history of any other cancer (except non-melanoma skin cancer or
carcinoma in-situ of the cervix), unless in complete remission and off of all therapy
for that disease for a minimum of 3 years (1 year for localized prostate carcinoma
treated by prostatectomy or irradiation) are ineligible.

2. Patients of childbearing potential must not be pregnant or become pregnant.

3. Patients must not have: a) active infection; b) disease that will obscure toxicity or
dangerously alter drug metabolism; c) serious intercurrent medical illness; d) acute
or chronic pulmonary disease, pulmonary embolus, hypertension, diabetes, metabolic
syndrome, stroke, heart disease,myocardial infarction, angina, coronary angioplasty,
congestive heart failure, or coronary bypass surgery; e) allergies to sulfa drugs; f)
severe psychiatric illness; g) uncontrolled hypertension (i.e. ->135/>85 mm Hg) on
three repeated measurements during the 6 weeks prior to enrollment on the study

4. Patients must not have (continued): h) family history of premature coronary disease
(i.e. - onset < 55 years of age); i) uncontrolled hypercholesteremia [low-density
lipoprotein cholesterol (LDL-C >130]. Hypercholesteremia must be controlled for at
least 3 months prior to enrollment on study; j) history of systemic lupus
erythematous, family history of protein S or C deficiencies, prior heparin-induced
thrombocytopenia, Factor V Leiden deficiencies or high homocysteine levels; k) any
indications for ASA deficiency

5. Patients must not have had prior treatment with Capecitabine, 5-FU or a combination
of Temozolomide with CCNU (Lomustine) or BCNU (Carmustine). Patients who received
only Temozolomide during radiation therapy and did not receive adjuvant chemotherapy
with Temozolomide and/or those who received Gliadel (BCNU) wafers at surgery without
adjuvant chemotherapy with BCNU or CCNU are eligible if 6 months has passed since the
treatment(s).